Form 4: Inozyme Pharma COO Matthew Winton Reports Stock Purchase Under Employee Stock Purchase Plan

Matthew Winton, COO of Inozyme Pharma, reports the acquisition of 2,490 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $0.77 per share.

Summary

• On March 31, 2025, Matthew Winton, the COO of Inozyme Pharma, acquired 2,490 shares of common stock.
• The shares were purchased through the company's 2020 Employee Stock Purchase Plan (ESPP).
• The purchase price was $0.77 per share, calculated as 85% of the closing price of Inozyme Pharma's common stock on March 31, 2025.
• Following the transaction, Winton directly owns 7,388 shares of Inozyme Pharma.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The COO's participation in the ESPP indicates confidence in the company, but the transaction is routine and doesn't necessarily signal major changes.

Positives

• The purchase demonstrates the COO's investment in the company's stock.
• The ESPP provides employees with the opportunity to acquire company stock at a discounted price.

Industry Context

Form 4 filings are standard practice for company insiders reporting transactions in their company's stock, providing transparency to investors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider trading activity.

Key Dates

Keywords

Inozyme Pharma, Matthew Winton, COO, ESPP, Employee Stock Purchase Plan, Stock Purchase, Form 4, Beneficial Ownership